dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation

Core Viewpoint - dsm-firmenich is focusing on accelerating performance following its transformation into a fully consumer-focused company, with a strategic plan to enhance financial performance and operational efficiency [2][3]. Company Transformation - The company has completed its portfolio upgrade after divesting Animal Nutrition & Health, achieving €175 million in cost synergies and establishing a stronger foundation for future growth [2][3]. Strategic Focus - The priority for 2026-2027 is on execution to drive growth, expand EBITDA margins, and improve cash conversion, while maintaining disciplined capital allocation and normalizing capital expenditure [3][6]. Business Unit Updates - Key executives will provide updates on business fundamentals and action plans to drive growth and innovation across various business units, including Perfumery & Beauty, Health, Nutrition & Care, and Taste, Texture & Health [4]. Financial Outlook - The company anticipates cautious consumer demand and adverse foreign exchange effects to continue into 2026, with expectations for Continuing Operations to deliver specific financial targets [5][6]. Mid-term Targets - dsm-firmenich aims to achieve mid-term targets for Organic Sales Growth and Adjusted EBITDA margin by 2028, with an increased target for Adjusted Gross Operating Free Cash Flow from ≥10% to ≥14% [6]. Share Repurchase Program - A new share repurchase program has been announced, totaling €540 million, with €500 million aimed at reducing issued capital and €40 million for share-based compensation commitments [7]. Performance Metrics - The company projects organic sales growth of 2–4%, an Adjusted EBITDA margin around 20%, and a cash conversion rate of 11–12% for Adjusted Gross Operating Free Cash Flow to Sales [8].